Aim:
Hematologic issues is main consequences for corona virus disease sufferers. Creation of ideal treatment strategies for venous thromboembolism (VTE), a severe coagulopathy linked to it, is required as soon as feasible. D-dimer, a byproduct of fibrin degradation, increases in critical COVID-19 pneumonia, which increases mortality. Aims: The main goal is to assess the levels of comorbid diseases and examine the changes in D-dimer in hospitalized patients before and following SC enoxaparin medication.

Material and methods:
Material and methods: At the Al-Yarmouk Teaching Hospital in Baghdad, Iraq, from October 2022 to May 2023, 86 patients who were hospitalized and had severe to critical COVID-19 infections provided data for a retrospective analysis.

Results:
Results: The medical records of all COVID-19 patients who were hospitalized and whose D-dimer level was greater than 0.5 mg/l and who were given enoxaparin (40 mg subcutaneously) were reviewed with the requisite authorization from the relevant authorities. The D-dimer level was assessed following therapy on the day of admission and day five after commencing enoxaparin. An examination of 86 case records revealed that persons with COVID-19 had significantly decreased D-dimer levels after taking subcutaneous enoxaparin (P-value<0.0001). The comorbidities (diabetes mellitus, hypertension) of patients who received the drug were compared.

Conclusions:
Conclusion: Enoxaparin and other anticoagulants were utilized to treat the coagulopathy brought on by COVID-19. Low molecular weight heparin enoxaparin has demonstrated positive outcomes in the management of VTE. A decrease in D-dimer level is anticipated when COVID-19 patients are treated with subcutaneous enoxaparin, partly because decreased coagulation results in lower fibrin formation.